Menu
  • Join
  • Login
  • Contact
 

Search abstracts / presentations


Dose selection in phase I clinical trials in oncology

  • In: Symposium E3: Medicines for the real life population: the science of extrapolation on Tuesday, 23 May 2017, 15:35-16:05
  • At: Stockholm (Sweden) (2017)
  • Type: Presentation
  • By: SCHELLENS, Jan (Netherlands Cancer Institute & University Utrecht, Clinical Pharmacology, Amsterdam, Netherlands)
  • Co-author(s): Jan HM Schellens: Clinical Pharmacology, Netherlands Cancer Institute & University Utrecht, Amsterdam, Netherlands
  • Abstract:

    Phase I studies in oncology are often carried out in patients with advanced cancer with the aim the select a safe dose and schedule for further testing in later phase II and III studies. Selection of the wrong dose and schedule can kill a good drug, which is a waist for patients and the pharmaceutical industry. Cabozantonib is a RET inhibitor

    ..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 28 September 2023

FIP Congresses